Venture Capital

How a small UK biotech ended up in Gilead’s hands


Gilead Sciences will acquire U.K.-based startup MiroBio, which is developing antibody drugs for autoimmune disorders, in a $405 million deal …

Read more

Show More

Related Articles

Back to top button